Background. Previous studies have suggested that in vivo Th2 lymphocyte activation is related to increased soluble CD30 (sCD30) plasma levels. As various hormones (dehydroepiandrosterone, glucocorticoids, progesterone) can regulate the Th1uTh2 balance, and because growth hormone (GH) enhances lymphocyte function, we measured sCD30 plasma levels, before and after treatment with recombinant human GH (rhGH), in children with growth failure due to chronic renal failure (CRF) or to isolated GH de®ciency in order to evaluate the potential effects of rhGH treatment on Th1uTh2 balance. Methods. sCD30 plasma levels were determined by ELISA assay in 30 children with CRF (mean age 10.7"3.7 years), in ®ve children with isolated GH de®ciency (mean age 11.4"2.6 years), and in 10 normal controls (mean age 10.1"3.5 years). Results. sCD30 levels were higher in the 30 children with CRF than in the 10 controls (179.8"79.4 vs 11.3"10.9 Uuml, P-0.001) exhibiting an inverse correlation with glomerular ®ltration rate (GFR) (rsÀ0.7860, P-0.001). In 11 children with CRF, after 19.9"16.7 months of rhGH treatment, a decrease of sCD30 plasma level (170"50 vs 134"49 Uuml, P-0.01) was observed. The ®ve children with primary GH de®ciency had higher sCD30 plasma level than controls (mean 147"105 vs 11"10 Uuml, P-0.004) and sCD30 plasma levels decreased to 95.2"109.6 Uuml after rhGH treatment. Conclusions. The ®nding that rhGH treatment decreased sCD30 plasma levels in children with CRF, and that children with primary GH de®ciency had higher sCD30 plasma levels than controls, suggest that GH may regulate CD30 expression and possibly the balance of Th1uTh2. Whether the uraemiainduced increase in sCD30 is due to decreased renal excretion, to overproduction or both, remains to be determined.
Introduction
The neuroendocrine and immune systems are linked by a bi-directional relationship. Cytokines can stimulate or inhibit the secretion of hormones from both the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-ovarian (HPO) axes and hormones can in¯uence immune function w1x. Moreover, the neuroendocrine system can in¯uence the Th1uTh2 balance. In fact it has been shown that dehydroepiandrosterone (DHEA) promotes the differentiation of T helper 1 cells (Th1), which produce IFN-c, IL-2 and are mainly involved in delayed hypersensitivity. In contrast, glucocorticoids and progesterone promote the expansion of T helper 2 cells (Th2), which produce IL-4, IL-5 and provide help for humoral immune responses (mainly IgE and IgG4) w2x.
Although Th1 and Th2 subtypes have been characterized on the ground of their cytokine secretion patterns, recent studies have reported preferential expression of the CD30 molecule on Th2-type T cells w3x.
CD30 is a surface receptor (belonging to the tumour necrosis factor superfamily) originally described as a marker for Reed-Stemberg cells in Hodgkin's disease (HD) w4x. Although the physiological expression of CD30 is mainly restricted to activated T and B cells, virally transformed T and B cells (EBV, HTLV, HIV) can also bear CD30. Whereas little is known about CD30 functions, it has been reported that CD30± CD30 ligand interaction provides a co-stimulatory signal for T cell proliferation. Moreover, CD30 expression is associated with production of a soluble form of CD30 (sCD30), generated by proteolytic cleavage, and it has been shown that patients with autoimmune diseases, HIV infection, and atopy have increased serum levels of sCD30, suggesting a preferential activation of Th2 cells in these immune disorders. In addition plasma levels of sCD30 are increased in some malignant lymphomas (mainly HD) and correlate with disease activity w5±7x.
There is also accumulating evidence that chronic renal failure (CRF) can affect both immune and neuroendocrine function. In particular, several immunological abnormalities have been reported in uraemic patients, such as defective cell-mediated and humoral immunity, monocyte dysfunction, chronic complement activation via the alternative pathway w8x, and activation of circulating T cells w9x.
In addition, uraemia itself can decrease the bioactivity of growth hormone (GH), of insulin-like growth factors (IGFs), and cause other hormonal dysfunctions which may cause growth failure in children with CRF w10,11x.
Based on these data many children with CRF, who fail to grow after measures to correct malnutrition, acidosis, and disturbances in calcium-phosphate balance, have been treated with supraphysiological doses of recombinant human GH (rhGH) w10,11x. Treatment with rhGH has also been given to children with functioning renal transplant and growth retardation, but there are concerns that GH has effects on the immune system, such as stimulation of lymphocyte proliferation, cytotoxic activity, and IFN-c production in mixed leukocyte cultures w12±17x.
In a recent review, it was hypothesized that GH is not an obligate immunoregulator, but acts rather as an anabolic and stress-modulating hormone in most cells including those of the immune system w18x. However, GH administration in critically ill adults is associated with increased morbidity and mortality and the preponderance of multiple-organ failure as well as septic shock or uncontrolled infection. These effects of GH suggest that a modulation of immune function may have been involved w19x.
We determined plasma levels of sCD30 in children with CRF or with primary GH de®ciency, before and during treatment with rhGH, in order to investigate whether rhGH would in¯uence immune activation pathways, and in particular the activity of the Th2 T cell subset as previously suggested by other authors w7,16x.
Subjects and methods
We measured sCD30 plasma levels in 30 children (19 males and 11 females, mean age 10.6"4.1 years), with preterminal CRF (see Table 1 ). The primary renal diseases were: re¯ux nephropathy (12) , renal dysplasia (6), nephronophthisis (4), obstructive uropathy (4), and dominant polycystic kidney disease (4) .
Patients included in the study had to meet the following criteria: (i) no immune system involvement in the pathogenesis of renal disease, (ii) no neoplastic or rheumatologic active disease, (iii) no active infectious disease, (iv) no history of allergic diseases, and (v) no sign of malnutrition. GFR was calculated by the Schwartz formula and ranged from 6 to 80 mluminu1.73 m 2 (see Table 1 ). In 11 out of 30 children (10 males and one female, mean age 9.8"3.1 years), sCD30 plasma levels were determined before and after a mean of 19.9"16.7 months treatment with rhGH (median dose 4 Uum 2 uday), and they were determined in ®ve children (two males and three females, mean age 12.8"3.7 years) when treatment with rhGH had been already instituted for a mean of 13"3 months.
Plasma levels of sCD30 were also evaluated in ®ve agematched children (two males and three females, mean age 11.4"2.6 years) with growth failure due to isolated GH de®ciency but normal renal function. GH de®ciency was con®rmed after at least two con®rmatory tests (GH peak secretion of less than 10 nguml after insulin, clonidine, or arginine challenge). Plasma levels of sCD30 were determined in 10 age-matched healthy children with normal renal function (seven males and three females). Informed consent of parents was always obtained.
Detection of soluble CD30 plasma levels was obtained immediately after venipuncture. Blood samples were centrifuged and plasma was separated from cells, collected and stored at À808C until further testing. Plasma levels of sCD30 were determined by ELISA assay (Dako CD30 ELISA kit, Dako Glostrup, Denmark). The coef®cient of variation was 3.8% within-run and 6.6% between-run. As plasma levels of sCD30 were determined in children with CRF (and in particular in children with CRF studied before and during rhGH treatment) using the same ELISA assay kit, a within-run variation coef®cient of 3.8% was assigned to these data.
We further investigated CD30 expression on mononuclear cells isolated from peripheral blood (PBMC) in ®ve subjects with CRF, before treatment with rhGH and after a mean of 12"5 months of rhGH therapy. This was also determined in ®ve age-matched normal subjects. Venous heparinized blood was collected in the morning from fasting patients and controls, and PBMC were separated on a Ficoll gradient and washed twice with Hanks' solution. Surface marker analysis was performed on PBMC by direct immuno¯uorescence using the CD30 monoclonal antibody (mAb), purchased from Dako. Cells were incubated with saturating amounts of mAb for 30 min at 48C, washed twice with PBS and analysed by¯ow cytometry using a FACSCAN (Becton-Dickinson) with the gate set on the lymphocyte population. Isotype-matched uorochrome-conjugated mAbs of unrelated speci®cities were used as controls to assess non-speci®c binding of test mAbs to each cell population and to set the threshold between positively and negatively staining cells.
Statistical analysis
Data were analysed by Mann±Whitney U tests, Wilcoxon matched pairs tests and by a linear regression model and multivariate linear regression model. Values of P-0.05 were considered statistically signi®cant.
Results
Plasma levels of sCD30 were ten to twentyfold higher in children with CRF compared with the control group (179.8"79.4 vs 11.3"10.9 Uuml, Mann±Whitney U test: P-0.001) (Figure 1 ). An inverse linear correlation was found with GFR (rsÀ0.7860, P-0.001) (Figure 2 ).
Plasma levels of sCD30 were signi®cantly lower in the 16 children with CRF under treatment with rhGH for a mean of 16.3"15.1 months than the 14 children with CRF not administered rhGH (122.4"59.6 vs 187.0"96.9 Uuml, Mann±Whitney U test: P-0.04) (Figure 1 ). Although the group of children treated with rhGH had a predominance of boys (13 males and four females vs six males and eight females in the untreated group), there were no differences in age, height, or and GFR between those treated with rhGH and untreated children (see Table 1 ). Moreover, when we measured sCD30 plasma levels in 11 children with CRF before and after treatment with rhGH (mean treatment duration 19.9"16.7 months), a signi®cant decrease in sCD30 plasma levels was observed, from 170.6"50.3 Uuml before treatment to 134.7"49.4 Uuml during treatment (Wilcoxon matched pair test P-0.01) (Figure 3 ). During the 100) was directly and signi®cantly related to the duration, in months of rhGH therapy (rs0.6499, P-0.05). In addition, a multivariate linear regression model that included the percentage of height increment in cm observed in children treated with rhGH (wT2ÀT1xuT1 3 100), the percentage change in GFR (wT2ÀT1xuT1 3 100) and DsCD30, during the same period of follow up, showed that DsCD30 was inversely related to the increment of height (rs±0.580, P-0.048) but not to GFR change (rs±0.096, P-0.766).
Interestingly, the group of ®ve age-matched children with primary GH de®ciency and normal renal function had signi®cantly higher sCD30 levels than in normal controls before treatment with rhGH (mean 147.6"105.0 vs 11.3"10.9 Uuml Mann±Whitney U test P-0.004) and, after a mean of 31.2"5.0 months of treatment with rhGH, the levels decreased to a mean of 95.2"109.6 Uuml (Figure 1) .
The expression of surface CD30 on circulating PBMC in ®ve uraemic children (before and after rhGH therapy) and in ®ve age-matched normal controls was investigated by¯ow cytometry. Uraemic children had a negligible proportion of PBMC staining for CD30 and no signi®cant difference from that found in PBMC values in age-matched normal controls. Moreover, there were differences of expression of CD30 on PBMC of uraemic children before and after rhGH treatment (data not shown).
Discussion
Elevated sCD30 plasma levels have been previously related to different disorders of the immune system, including malignant lymphomas, SLE, connective tissue disease, atopic disorders and HIV infection w6x. Both activated T cells and activated B cells can express surface CD30, and it has been suggested that CD30 expression does not discriminate between Th1 and Th2 type T cells w20x. However, other in vivo and in vitro studies have supported the hypothesis that CD30 is mainly expressed in Th2 lymphocytes w3x and that sCD30 plasma levels may re¯ect the Th2 T cell activation status w7,16x. Fig. 1 . Plasma levels of sCD30 were higher in children with CRF than in controls (Mann±Whitney U test, P-0.001). Children with CRF under treatment with rhGH had lower sCD30 plasma levels than in untreated children with CRF (P-0.04). sCD30 plasma levels were also signi®cantly higher in children with primary GH de®ciency than in normal controls (P-0.004) and decreased after treatment with rhGH.
As there is accumulating evidence that neuroendocrine axes can in¯uence the immune system, and in particular the balance between Th1-Th2 immune responses w2x, the effect of rhGH treatment on plasma levels of sCD30 in children with CRF, who fail to grow under common conservative treatment, was evaluated in the present study.
Our data demonstrated that sCD30 plasma levels were higher in children with CRF than in controls (P-0.001), and were inversely related to GFR Fig. 3 . sCD30 plasma levels in patients with CRF before (170.6"52.6 Uuml) and after treatment (134.7"49.4 Uuml) with rhGH (Mann±Whitney U test P-0.01).
(P-0.001). We also found that plasma levels of sCD30 were signi®cantly lower in children with CRF under rhGH treatment than in untreated children with CRF (P-0.04). Although the group of children treated with rhGH had a predominance of boys (13 males and four females vs six males and eight females in the untreated group), there were no differences in age or height between rhGH-treated and untreated children (see Table 1 ). However, as rhGH treated children had lower GFRs than untreated children (mean GFR 19 vs 28 mluminu1.73 m 2 , Ps0.338), this ®nding is important because we had expected higher sCD30 plasma levels in the former group. Most of the 14 children not treated with GH subsequently underwent rhGH treatment; however, plasma samples for CD30 were not available during the follow-up study.
In a group of 11 children with CRF, plasma samples were available after a mean of 19.9"16.7 months of treatment with rhGH, and a decrease in sCD30 plasma levels were observed (P-0.01) (Figure 3 ). The ®nding that the percentage of decrease of sCD30 plasma levels in that group was not related to GFR variations, but rather to the duration of rhGH therapy, in months, (rs0.6499, P-0.05) and to the increment of height (rs±0.580, P-0.048), supports the hypothesis that rhGH treatment may modulate sCD30 plasma levels. However, these observations were possible because our patients had rather stable renal function during the follow-up. In contrast, if we had observed a more rapid decline of GFR in our paediatric patients, we would probably not have detected a decrease in sCD30 plasma levels because the reduction in glomerular ®ltration should have increased plasma levels of sCD30 (see Figure 1) . The ®nding that the single patient that showed an increase in sCD30 plasma levels during rhGH treatment (Figure 3 ) was the same that had a 61% decrease in GFR during the same period, is consistent with the hypothesis that uraemia-induced reduction in GFR cause an accumulation of sCD30 in plasma that is reduced in part by rhGH treatment.
Moreover, as previous studies demonstrated that uremia itself can activate T cells w9x, we speculate that in CRF, an enhanced T cell expression of CD30 can occur, resulting in increased shedding of sCD30 molecules that may contribute to sCD30 accumulation in uraemia.
In this context, although it is conceivable that sCD30 accumulation in CRF is due mainly to reduced urinary excretion of the molecule, the ®nding of a progressive reduction of sCD30 plasma levels in children with CRF under treatment with rhGH suggests that rhGH can downregulate the expression of CD30 (and in turn sCD30 shedding) in activated T cells or in other unidenti®ed cells.
As the percentage of PBMC staining for CD30 was comparable in uraemic children and controls, and did not change during treatment with rhGH, the issue of whether or not uraemia is responsible for enhanced expression of CD30 in T cells or in other cell types requires additional investigation.
Alternatively, it is possible that rhGH treatment may decrease sCD30 plasma levels by augmenting the renal excretion of sCD30. To reach ®rm conclusions about the renal handling of a molecule, additional data are needed, including charge, sieving coef®cient, and reabsorptionudegradation rate. Because these were not available for the sCD30 molecule, we cannot determine whether sCD30 accumulation in CRF was related to reduced urinary excretion or to overproduction, or whether sCD30 plasma levels decreased during rhGH treatment because of decreased sCD30 production or increased renal excretion.
However, the ®nding that in children with primary GH de®ciency and normal renal function also had sCD30 plasma levels that were higher than in normal controls (P-0.04), and that decreased during treatment with rhGH, suggests that GH de®ciency can increase sCD30 plasma levels and that rhGH treatment may play a direct role in the regulation of sCD30 plasma levels. These observations suggest that the per cent decrease of sCD30 plasma levels was related to rhGH treatment duration (P-0.05) and to the effects of rhGH on the growth of the children (P-0.048). In addition, they support the hypothesis that the reduced bioavailability of GH in uraemia may have effects not only on growth but also on the immune system.
Taken together, these data strongly suggest that GH can in¯uence the mechanisms of T cell activation. However whether rhGH treatment can affect the balance between Th1 and Th2 subpopulations and whether it can down-regulate Th2 cells remains to be established w3,18±21x. Although previous studies did not show signi®cant differences in other immune activation parameters in children treated with rhGH w17x, the ®nding that rhGH treatment in critically ill adults was associated with increased mortality due to rapid onset of septic shock and multipleorgan failure, further supports, on clinical grounds, the hypothesis that the hypermetabolic and proin¯ammatory effects of rhGH treatment can affect immune function w19,22x.
In conclusion, our data suggest that GH may act as an important regulator of the immune system, and point to new approaches for the investigation of rhGH effects in the treatment of children with CRF and with primary GH de®ciency.
